Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Five Questions with Bill Niland, Harpoon Medical CEO

By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used on humans for the first time in a matter of weeks. The Kent Island-based company expects doctors in Poland to…

Scottish Synthetic Bone Graft Company Secures $4.8m Funding

EDINBURGH, UK, December 2, 2014 –  SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in Series-A financing from a syndicate of investors led by Epidarex Capital. Synthetic bone grafts are used in trauma, spinal and…

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals.

CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 has the same…

Epidarex Capital Leads New Investment in Edinburgh Molecular Imaging

Edinburgh, United Kingdom, February 7, 2014.  Epidarex Capital, a leading international early-stage life science venture capital fund, has announced a £4 million Series A investment, in Edinburgh Molecular Imaging (EMI). Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round. EMI, an…

The following articles make reference to Epidarex Capital under its previous name.

Apellis Pharmaceuticals Inc. Raises Series C Financing

Louisville, Kentucky – August 21st, 2013 – Rock Spring Ventures has increased its investment in Apellis Pharmaceuticals Inc., an early-stage biotechnology company focused on developing a novel pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development. Apellis…